AstraZeneca cancer drug carries toxic risks: FDA

November 30, 2010

An experimental drug developed by AstraZeneca to treat a rare form of thyroid cancer carries "substantial toxicity" risks, the US Food and Drug Administration warned Tuesday.

Thirty-one percent of patients taking the drug, vandetanib, experienced serious side effects compared to 13 percent who did when taking a placebo.

Side effects included a potentially dangerous skin rash known as Stevens-Johnson syndrome, strokes and lung disease.

Many patients involved in studies also had to switch to lower doses, the FDA said in a report ahead of a December 2 meeting of outside experts to discuss the findings and recommend whether the drug should come to market.

Eighty percent of patients in a Phase II study that began with a 300-milligram dose of the drug "required a dose reduction or interruption."

A subsequent study that gave patients a 100-milligram dose saw 21 percent require dosage to be reduced or stopped.

"Given the substantial toxicity seen with vandetanib, should its indication be limited to patients with progressive, symptomatic medullary thyroid cancer?" the FDA asked. "Should additional doses of vandetanib be explored?"

The FDA does not have to follow the expert panel's recommendations but it often does.

expects to have a decision by January on its new drug application for vandetanib in patients with medullary thyroid cancer, a relatively rare disease that typically carries lower survival rates than other forms of .

Some 45,000 new cases are expected to be diagnosed this year in the United States.

The company says the drug works by slowing .

Vandetanib was initially set to be a treatment for but AstraZeneca withdrew its request for the drug to be put on the market for such use in 2009 after studies showed it failed to extend survival rates.

Related Stories

Recommended for you

Researchers identify drug that alleviates opioid withdrawal

January 30, 2017

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary's Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) have discovered that ...

Detecting counterfeit medicines

January 27, 2017

Bernard Naughton and Dr David Brindley from Oxford University's Saïd Business School and Medical Sciences Division discuss the problems of identifying fake, substandard and expired medicines.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.